Innovation, Financial Results, Investor Conferences, Geographic Expansion, and Long-term Investments - Research Report on CareFusion, BD, Covidien, Mindray, and The Cooper Companies

NEW YORK, August 8, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting CareFusion Corporation (NYSE: CFN), Becton, Dickinson and Company (NYSE: BDX), Covidien plc (NYSE: COV), Mindray Medical International Limited (NYSE: MR), and The Cooper Companies Inc. (NYSE: COO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

CareFusion Corporation Research Report

On August 1, 2013, CareFusion Corp. (CareFusion) announced that it has been cited as the technology leader in integrating smart pumps with electronic medical records as announced by the 2013 Smart Pump/EMR Integration Report from KLAS Research. According to the release, CareFusion is also recognized as the only company that currently has a customer using EMR interoperability with large volume and syringe infusion pumps. J.C. Kyrillos, Senior Vice President and General Manager of Infusion for CareFusion, said, "We are extending our leadership in today's infusion devices to include the next frontier of EMR interoperability. Using one platform for large volume pumps, syringe pumps and PCA is a key component to our strategy of providing the best and least complicated solution for our hospital customers." The Full Research Report on CareFusion Corporation - including full detailed breakdown, analyst ratings and price targets - is available to  download free of charge at: [http://www.analystscorner.com/r/full_research_report/4933_CFN]

--

Becton, Dickinson and Company Research Report

On August 1, 2013, Becton, Dickinson and Company (BD) reported its Q3 FY 2013 financial results (period ended June 30, 2013). The Company reported total revenues of $2.1 billion, up 3.6% YoY. Net income from continuing operations was $291.9 million or $1.47 per diluted share, compared with $311.6 million or $1.52 per diluted share in Q3 FY 2012. Vincent A. Forlenza, Chairman, CEO and President, said, "Our solid results against the backdrop of a challenging environment demonstrate that we are executing on our strategy and delivering on our commitments. We remain confident in our fiscal year 2013 outlook." The Company reaffirmed its earnings guidance for full-year FY 2013 and anticipates revenue growth to be in the range of 3.5% to 4% YoY and EPS from continuing operations in the range of $5.65 to $5.68. The Full Research Report on Becton, Dickinson and Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/0175_BDX]

--

Covidien plc Research Report

On August 1, 2013, Covidien plc (Covidien) reported its Q3 FY 2013 (period ended June 28, 2013) financial results with total net sales up 2.9% YoY to $2.6 billion. Operating income for the quarter totaled $542 million compared with $538 million in Q3 FY 2012. Net Income from continuing operations was $400 million or $0.85 per diluted share, compared to $395 million or $0.81 per diluted share in Q3 FY 2012. José E. Almeida, Chairman, President and CEO said, "We delivered a solid performance in the third quarter. Operational sales growth was in line with our expectations, but our reported sales growth was restrained by the strength of the U.S. dollar against most foreign currencies. In the Medical Devices segment, continued strong results in stapling and vessel sealing paced our quarterly performance. With the Pharmaceuticals spin-off now behind us, we are focused on strengthening our Medical Devices and Supplies businesses through organic growth, new products and geographic expansion." The Full Research Report on Covidien plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/a14c_COV]

--

Mindray Medical International Limited Research Report

On August 5, 2013, Mindray Medical International Limited (Mindray) reported its Q2 2013 financial results with net revenue growth of 14.7% YoY to $307.2 million. Sales in China grew by 27.9% YoY to $147.4 million while international sales totaled $159.7 million, up 4.7% YoY. Non-GAAP operating income increased 15.2% YoY to $73.1 million and non-GAAP net income grew 14.7% to $68.2 million. Mr. Li Xiting, Mindray's President and Co-Chief Executive Officer said, "In the second quarter, our strong China sales continued to drive our top-line performance and we are pleased that our sales in the emerging markets improved sequentially. We further enhanced our efficiency with better management of our cash conversion cycle. We are also very excited about our recent acquisition of ZONARE, which greatly strengthened our ultrasound R&D capabilities and expanded our high-end product portfolio." The Company is raising its full year 2013 outlook and anticipates an 18% YoY growth on its net revenues and 15% YoY growth on its non-GAAP net income. The Full Research Report on Mindray Medical International Limited - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/8d4d_MR]

--

The Cooper Companies Inc. Research Report

On August 5, 2013, The Cooper Companies Inc. (Cooper Companies) announced that it will present its Q3 FY 2013 (period ended June 30, 2013) earnings release on September 5, 2013, Thursday at 4:00 p.m. ET. The Company informed that after the release, it will hold a conference call and live webcast at 5:00 p.m. ET to discuss the results and its current corporate developments. Cooper Companies also stated that a replay of the call will be available approximately two hours after the call ends, which will be accessible until Thursday, September 12, 2013. The Full Research Report on The Cooper Companies Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9cde_COO]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

AnalystsCorner.com

SOURCE Analysts' Corner